Badrinath R. Konety

Badrinath R. Konety's AcademicInfluence.com Rankings

Badrinath R. Konety

Philosophy

#7091

World Rank

#10252

Historical Rank

Logic

#4167

World Rank

#5426

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Badrinath R. Konety's Degrees

Doctorate Medicine University of California, San Francisco
Masters Business Administration University of California, Berkeley

Why Is Badrinath R. Konety Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Badrinath R. Konety's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Early detection of prostate cancer: AUA Guideline. (2013) (1061)
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. (2016) (915)
Active surveillance for the management of prostate cancer in a contemporary cohort (2008) (411)
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial (2018) (399)
Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. (2003) (332)
Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. (2006) (266)
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. (1997) (241)
Treatment failure after primary and salvage therapy for prostate cancer (2008) (238)
Complications after radical cystectomy: analysis of population-based data. (2006) (238)
Recurrence of high‐risk bladder cancer: A population‐based analysis (2013) (228)
Squamous cell carcinoma of the penis (2004) (222)
Impact of hospital and surgeon volume on in-hospital mortality from radical cystectomy: data from the health care utilization project. (2005) (199)
Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer (2015) (195)
Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Cancer through Aberrant Canonical Wnt/β-Catenin Signaling Pathway (2006) (195)
PSA screening among elderly men with limited life expectancies. (2006) (188)
Bladder cancer-associated nuclear matrix proteins. (1996) (178)
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. (2013) (173)
High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. (2002) (169)
Urine based markers of urological malignancy. (2002) (152)
The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. (2006) (139)
Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. (2003) (134)
Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. (2000) (134)
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. (2021) (134)
Compliance with guidelines for patients with bladder cancer (2011) (128)
Quality of life in long‐term survivors of bladder cancer (2006) (124)
A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. (2008) (112)
Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. (2000) (112)
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. (2020) (110)
Molecular markers in bladder cancer: a critical appraisal. (2006) (109)
Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). (2019) (109)
Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. (2007) (104)
The role of vitamin D in normal prostate growth and differentiation. (1996) (103)
Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. (2001) (100)
Meta‐analysis: does lidocaine gel before flexible cystoscopy provide pain relief? (2009) (100)
Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. (2005) (99)
Recovery of urinary continence following radical prostatectomy: the impact of prostate volume--analysis of data from the CaPSURE Database. (2007) (98)
Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis (2019) (97)
The impact of provider volume on outcomes from urological cancer therapy. (2005) (94)
Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. (2014) (91)
Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results (2009) (90)
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. (2020) (84)
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study (2017) (84)
Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. (2008) (82)
Surgical management after active surveillance for low‐risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment (2011) (81)
Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample. (2007) (81)
Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. (2004) (80)
Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. (2005) (79)
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer (2009) (79)
Renal cryoablation: Outcome at 3 years (2006) (79)
Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better? (2006) (79)
Bladder and upper tract urothelial cancer. (2007) (76)
Vitamin D in the prevention and treatment of prostate cancer. (1999) (76)
Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. (2020) (76)
The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update (2015) (74)
Landmarks in prostate cancer (2018) (71)
Use of bipolar energy for transurethral resection of bladder tumors: pathologic considerations. (2004) (71)
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA (2014) (70)
Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. (2018) (68)
Nuclear structural proteins as biomarkers of cancer (1999) (67)
Functional Characterization of the Bladder Cancer Marker, BLCA-4 (2004) (67)
The prevalence of renal cell carcinoma diagnosed at autopsy (2005) (65)
Specificity of Procedure Volume and In-hospital Mortality Association (2007) (65)
The impact of marriage on bladder cancer mortality. (2009) (63)
Effect of a minimum lymph node policy in radical cystectomy and pelvic lymphadenectomy on lymph node yields, lymph node positivity rates, lymph node density, and survivorship in patients with bladder cancer (2010) (63)
Effect of Meeting Leapfrog Volume Thresholds on Complication Rates Following Complex Surgical Procedures (2010) (61)
Scrotal elephantiasis associated with hidradenitis suppurativa. (1996) (61)
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high‐risk superficial bladder tumours undergoing intravesical therapy (2009) (60)
3D Printed Organ Models with Physical Properties of Tissue and Integrated Sensors (2018) (59)
Quality of care in patients with bladder cancer (2012) (59)
Prostate cancer in the post-transplant population (1998) (58)
Influence of post-cystectomy complications on cost and subsequent outcome. (2006) (58)
Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. (2010) (57)
Non-muscle invasive bladder cancer risk stratification (2015) (57)
Trends in regionalization of inpatient care for urological malignancies, 1988 to 2002. (2007) (56)
Bias and stereotyping among research and clinical professionals: Perspectives on minority recruitment for oncology clinical trials (2020) (56)
The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis (2016) (55)
The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. (2015) (53)
Molecular Characterization of Neuroendocrine-like Bladder Cancer (2019) (53)
Compliance with guidelines for patients with bladder cancer: variation in the delivery of care (2011) (52)
Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer. (2006) (49)
A Simplified Frailty Index to Predict Outcomes After Radical Cystectomy. (2018) (49)
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. (2019) (48)
Detection of Prostate Cancer: Quantitative Multiparametric MR Imaging Models Developed Using Registered Correlative Histopathology. (2016) (48)
Differences in trends in the use of robot‐assisted and open radical cystectomy and changes over time in peri‐operative outcomes among selected centres in North America and Europe: an international multicentre collaboration (2019) (47)
Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. (2003) (47)
Recurrent metastatic renal cell carcinoma presenting as a bleeding gastric ulcer after a complete response to high-dose interleukin-2 treatment. (2001) (46)
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018 (2019) (46)
The S100A4 Oncoprotein Promotes Prostate Tumorigenesis in a Transgenic Mouse Model: Regulating NFκB through the RAGE Receptor. (2013) (44)
Advantages and risks of ileovesicostomy for the management of neuropathic bladder. (1999) (44)
Cavernous nerve repair with allogenic adipose matrix and autologous adipose-derived stem cells. (2011) (43)
Three‐dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture (2011) (41)
Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder (2018) (41)
Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens. (2019) (39)
Detection and localisation of primary prostate cancer using 68gallium prostate‐specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology (2020) (39)
Candidate quality of care indicators for localized bladder cancer. (2009) (39)
Prostatic artery embolization to treat lower urinary tract symptoms related to benign prostatic hyperplasia and bleeding in patients with prostate cancer: proceedings from a multidisciplinary research consensus panel. (2014) (39)
Effect of axillary lymphadenectomy on breast carcinoma survival (2005) (39)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (2017) (38)
The example of CaPSURE: lessons learned from a national disease registry (2011) (38)
Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder (2004) (38)
Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper? (2004) (37)
Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. (1999) (37)
The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis (2018) (37)
Effect of perioperative blood transfusion on mortality for major urologic malignancies. (2015) (36)
Racial Disparities in Active Surveillance for Prostate Cancer (2017) (36)
Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival. (2008) (36)
Identification of nuclear matrix protein alterations associated with renal cell carcinoma. (1998) (36)
Predictors of Recurrence, Progression-Free and Overall Survival Following Open Versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Follow-Up. (2020) (35)
ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: Study in African‐American and Caucasian prostate cancer models (2014) (35)
Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. (2020) (34)
Bias and stereotyping among research and clinical professionals: Perspectives on minority recruitment for oncology clinical trials. (2019) (34)
18F-FDG PET/CT of transitional cell carcinoma. (2009) (33)
Characteristics of patients and predictors of in‐hospital mortality after hospitalization for head and neck cancers (2006) (33)
Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost‐Effectiveness Analysis (2018) (33)
Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. (2009) (33)
Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. (2019) (32)
Intravesical electromotive drug administration for non-muscle invasive bladder cancer. (2017) (32)
Association of vitamin D receptors with the nuclear matrix of human and rat genitourinary tissues (1998) (32)
Health related quality of life assessments for patients with bladder cancer. (2004) (32)
Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome? (2006) (32)
Training Needs of Clinical and Research Professionals to Optimize Minority Recruitment and Retention in Cancer Clinical Trials (2019) (32)
Novel biomarkers for prostate cancer: An evidence‐based review for use in clinical practice (2017) (32)
Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications (2018) (31)
BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 Signaling (2013) (31)
The Sexual Functioning of Gay and Bisexual Men Following Prostate Cancer Treatment: Results from the Restore Study (2019) (31)
Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. (2009) (31)
FDG‐PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients (2018) (30)
Percutaneous radiofrequency ablation of renal tumors: Technique, complications, and outcomes (2006) (30)
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease (2017) (29)
Urinary Biomarkers in the Evaluation of Primary Hematuria: A Systematic Review and Meta-Analysis (2018) (29)
Use of urine-based markers for detection and monitoring of bladder cancer. (1999) (28)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. (2017) (28)
The effects of radical prostatectomy on gay and bisexual men's mental health, sexual identity and relationships: qualitative results from the restore study (2016) (28)
Effect of postcystectomy infectious complications on cost, length of stay, and mortality. (2008) (28)
Prevalence of prostate specific antigen testing for prostate cancer in elderly men. (2006) (27)
Use of bipolar power source for transurethral resection of bladder tumor in patient with implanted pacemaker. (2005) (27)
Diagnostic Value of Voided Urine and Bladder Barbotage Cytology in Detecting Transitional Cell Carcinoma of the Urinary Tract (1999) (27)
Evaluation of the effect of spinal cord injury on serum PSA levels. (2000) (27)
In Vivo Tumor Grading of Prostate Cancer Using Quantitative 111In-Capromab Pendetide SPECT/CT (2010) (27)
BMI1, Stem Cell Factor Acting as Novel Serum-biomarker for Caucasian and African-American Prostate Cancer (2013) (26)
Factors affecting outcomes after radical cystectomy in African Americans (2007) (26)
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. (2020) (25)
Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death. (2014) (24)
Bias due to missing SEER data in D'Amico risk stratification of prostate cancer. (2012) (24)
Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests? (1999) (24)
Novel therapies for advanced prostate cancer. (1997) (23)
Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: impact on patient outcomes and costs. (2004) (23)
The future of clinical practice guidelines in urology. (2011) (23)
Urinary markers/cytology: what and when should a urologist use. (2013) (23)
The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer (2018) (23)
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. (2020) (23)
Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy. (2017) (22)
Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. (2017) (22)
Urolume stent placement for the treatment of postbrachytherapy bladder outlet obstruction. (2000) (22)
Vitamin D and prostate cancer. (2002) (22)
Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. (2019) (22)
Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants (2017) (21)
Prostate cancer screening parameters in a high-risk African-Caribbean population. (2004) (21)
Increased Surgical Complications in Smokers Undergoing Radical Cystectomy1 (2018) (21)
Urothelial bladder cancer: biomarkers for detection and screening (2008) (21)
Understanding Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men and Transgender Women: A Review of the Literature (2018) (21)
Development of a Classification Scheme for Examining Adverse Events Associated with Medical Devices, Specifically the DaVinci Surgical System as Reported in the FDA MAUDE Database. (2017) (20)
Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial - A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy. (2020) (20)
Quality of Evidence to Compare Outcomes of Open and Robot-Assisted Laparoscopic Prostatectomy (2011) (20)
Treatment and survival in patients with recurrent high-risk non-muscle-invasive bladder cancer. (2015) (20)
The effects of radical prostatectomy on gay and bisexual men's sexual functioning and behavior: qualitative results from the restore study (2016) (20)
Screening and management of prostate cancer in elderly men: the Iowa Prostate Cancer Consensus. (2006) (20)
Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057. (2020) (20)
Personality, treatment choice and satisfaction in patients with localized prostate cancer (2007) (20)
Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression (2008) (19)
Racial Disparities in Surgical Outcomes Among Males Following Major Urologic Cancer Surgery. (2018) (19)
Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes (2014) (19)
Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis (2018) (19)
Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette‐Guérin Therapy for Patients With High‐Grade, Non–Muscle‐Invasive Bladder Cancer (2017) (19)
BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models (2018) (19)
Long‐term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high‐risk prostate cancer (2015) (19)
Impact of malpractice caps on use and outcomes of radical cystectomy for bladder cancer: data from the surveillance, epidemiology, and end results program. (2005) (19)
Simultaneous radical nephrectomy and repair of abdominal aortic aneurysm. (1996) (18)
Disparities in Bladder Cancer Treatment and Survival Amongst Elderly Patients with a Pre-existing Mental Illness. (2020) (18)
Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. (2006) (18)
In vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate. (2000) (18)
Effect of prenatal vitamin D (calcitriol) exposure on the growth and development of the prostate (1999) (18)
Challenges of managing elderly men with prostate cancer (2014) (17)
Oncological and functional outcomes of radical cystectomy and orthotopic bladder replacement in women. (2011) (17)
Social Support and Health-Related Quality of Life Among Gay and Bisexual Men With Prostate Cancer. (2018) (17)
Cutaneous metastases from transitional cell carcinoma of the bladder. (2006) (17)
Optimizing outcomes at every stage of bladder cancer: do we practice it? (2009) (16)
COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer (2019) (16)
Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique. (2002) (15)
The Association of Robot-assisted Versus Pure Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Hospital Costs. (2020) (15)
Preoperative Incidence of Deep Venous Thrombosis in Patients With Bladder Cancer Undergoing Radical Cystectomy. (2018) (15)
Patient‐reported outcomes of blue‐light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study (2018) (14)
Intensity modulated radiation therapy replaces 3-dimensional conformal radiotherapy as prostate cancer treatment. (2012) (14)
Enhanced recovery after surgery (ERAS) following radical cystectomy: is it worth implementing for all patients? (2020) (14)
Fluorescence cystoscopy and bladder surveillance (2004) (14)
Skeletal Muscle and Fat Mass Indexes Predict Discharge Disposition after Radical Cystectomy. (2019) (14)
Estimating postoperative mortality and morbidity risk of radical cystectomy with continent diversion using predictor equations. (2009) (14)
Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: A study and review (2006) (14)
A DELAY IN RADICAL CYSTECTOMY OF >3 MONTHS IS NOT ASSOCIATED WITH A WORSE CLINICAL OUTCOME (2007) (14)
Practice patterns in screening and management of prostate cancer in elderly men. (2006) (14)
Perineural invasion in transitional cell carcinoma and the effect on prognosis following radical cystectomy. (1998) (14)
Management of localized prostate cancer in men over 65 years (2009) (14)
The Connection Between Selective Referrals for Radical Cystectomy and Radical Prostatectomy and Volume–Outcome Effects (2012) (13)
General adherence to guideline recommendations on initial diagnosis of bladder cancer in the United States and influencing factors. (2014) (13)
Fibrin glue v sutured bolster: Lessons learned during 100 laparoscopic partial nephrectomies (2006) (13)
Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study. (2018) (13)
Tolerability of Repeat Use of Blue Light Cystoscopy with Hexaminolevulinate for Patients with Urothelial Cell Carcinoma (2017) (13)
Risk of end stage kidney disease after radical cystectomy according to urinary diversion type. (2015) (13)
Nonandrogenic mediators of prostatic growth. (2001) (13)
Castration-resistant prostate cancer: potential targets and therapies (2012) (13)
The current status of immunobased therapies for metastatic renal-cell carcinoma (2017) (12)
Comparative Evaluation of Bladder-specific Health-related Quality of Life Instruments for Bladder Cancer. (2017) (12)
A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance (2020) (12)
The volume/outcome relationship in urologic cancer surgery. (2004) (12)
Perceived Institutional Barriers Among Clinical and Research Professionals: Minority Participation in Oncology Clinical Trials. (2021) (12)
Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes (2019) (11)
Persistent muscle‐invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results‐Medicare data (2018) (11)
What Gay and Bisexual Men Treated for Prostate Cancer are Offered and Attempt as Sexual Rehabilitation for Prostate Cancer: Results from the Restore Study (2017) (11)
Expression of SSEA-1 (Lewis(x)) on transitional cell carcinoma of the bladder. (1997) (11)
Every urologist and oncologist should know about treating sexual and gender minority prostate cancer patients: translating research findings into clinical practice (2021) (11)
Letters to the Editor/Errata Re: Early Detection of Prostate Cancer: AUA guideline (2013) (11)
Prostate cancer screening: issues and controversies. (2010) (11)
Effect of minimally invasive radical prostatectomy in older men. (2016) (11)
Embryonal adenoma of the kidney associated with polycythemia and von Willebrand disease. (1998) (11)
Contemporary Management of Prostate Cancer (2016) (11)
Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists (2018) (11)
What Gay and Bisexual Men Treated for Prostate Cancer Want in a Sexual Rehabilitation Program: Results of the Restore Needs Assessment (2017) (10)
Prostate cancer in the post-transplant population. Urologic Society for Transplantation and Vascular Surgery. (1998) (10)
Adverse impact of malnutrition markers on major abdominopelvic cancer surgery (2019) (10)
Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. (2020) (10)
A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imaging‐guided biopsy (2018) (10)
Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials. (2019) (10)
BLCA-4 Functional Characterization of the Bladder Cancer Marker , (2004) (10)
Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up. (1999) (10)
Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches (2018) (10)
Current Concepts in the Management of Muscle Invasive Bladder Cancer (2017) (9)
Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists. (2018) (9)
Surgical Enucleation for the Treatment of Renal Tumors (2003) (9)
A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT. (2019) (9)
Should men over the age of 65 years receive PSA screening? Argument in favor (2008) (8)
UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer. (2009) (8)
Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. (2016) (8)
Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. (2021) (8)
Adjuvant Radiotherapy for Synchronous Bilateral Testicular Seminoma: A Case Report and a Review of the Pertinent Literature (2013) (8)
Ureteral entrapment in the sacroiliac joint in pelvic trauma. (1996) (8)
Urological infections in the developing world: an increasing problem in developed countries (2020) (8)
FISH VS. CYTOLOGY IN POST-CYSTECTOMY TUMOR SURVEILLANCE (2008) (8)
Association of Comorbidity, Age, and Radical Surgical Therapy for Prostate Cancer, Bladder Cancer, and Renal Cell Carcinoma. (2016) (8)
Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences (2009) (7)
Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer. (2018) (7)
Health‐related quality of life by human immunodeficiency virus status in a cross‐sectional survey of gay and bisexual prostate cancer survivors (2019) (7)
Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence (2022) (7)
Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. (2020) (7)
Testicular recurrence from "primary" retroperitoneal germ cell tumor. (2004) (7)
Factors associated with reduction in use of neoadjuvant androgen suppression therapy before radical prostatectomy. (2013) (7)
Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer. (2020) (7)
Complete response of bony metastatic bladder urothelial cancer to neoadjuvant chemotherapy and cystectomy. (2006) (6)
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. (2019) (6)
Prevalence of Clostridium Difficile Infection in Patients After Radical Cystectomy and Neoadjuvant Chemotherapy (2017) (6)
Effect of uniform consensus recommendations for PCa screening in older population: differential effects and perceptions of healthcare providers and patients. (2009) (6)
Acute Kidney Injury following Enhanced Recovery after Surgery (ERAS) in Patients Undergoing Radical Cystectomy. (2020) (6)
Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. (2015) (6)
Factors associated with the Journal Impact Factor (JIF) for Urology and Nephrology Journals (2015) (6)
Making a case “against” focal therapy for intermediate-risk prostate cancer (2020) (6)
Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer: a Cochrane Review (2019) (6)
A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT (2019) (6)
Association of age and response to androgen‐deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE (2010) (6)
Are age-based criteria the best way to determine eligibility for prostate cancer screening? (2009) (5)
Retraction: Functional Characterization of the Bladder Cancer Marker, BLCA-4 (2013) (5)
Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A. (2021) (5)
Leiomyosarcoma with osteoclast-like giant cells of the spermatic cord. A case report and review of the literature. (1996) (5)
Phase I study of Ad5-TRAIL in men with clinically organ confined prostate cancer (2007) (5)
Acceptability and Feasibility of Collecting Sexual Orientation and Expanded Gender Identity Data in Urology and Oncology Clinics. (2021) (5)
Creation and Psychometric Validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study. (2022) (5)
MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review (2021) (5)
African American Men's Health: Research, Practice, and Policy. (2018) (5)
Re: Critical Analysis of Early Recurrence After Laparoscopic Radical Cystectomy in a Large Cohort by the ESUT. (2017) (5)
The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma (2021) (5)
Pain and Loss of Pleasure in Receptive Anal Sex for Gay and Bisexual Men following Prostate Cancer Treatment: Results from the Restore-1 Study (2021) (5)
A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. (2019) (5)
Comorbidity Prevalence and Impact on Quality of Life in Gay and Bisexual Men Following Prostate Cancer Treatment. (2021) (5)
Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057. (2019) (5)
Evaluation of computerized tomography for staging of clinically localized adenocarcinoma of the prostate. (1996) (5)
OUTCOMES FROM A PHASE I TRIAL OF AN ADENOVIRUS/PSA VACCINE FOR PROSTATE CANCER (2008) (4)
Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG) (2019) (4)
488: Prostate Cancer Progresssion in a Watchful Waiting Cohort: The UCSF Experience (2006) (4)
Erratum: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma [Journal for Immunotherapy of Cancer., 5 (2017)(68)] DOI: 10.1186/s40425-017-0271-0 (2017) (4)
Prostate Biopsy Processing. (2019) (4)
Role of blue‐light cystoscopy in detecting invasive bladder tumours: data from a multi‐institutional registry (2021) (4)
Quality of Care Indicators for Radical Cystectomy (2009) (4)
THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA: MP86‐17 (2017) (4)
Penile cancer in a man with netherton syndrome. (2015) (4)
Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy. (2022) (4)
A novel terpenoid class for prevention and treatment of KRAS‐driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems (2020) (4)
Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent (2006) (4)
Magnetic resonance imaging cognitive fusion biopsy – is near enough good enough? (2018) (4)
Phase II trial of neoadjuvant nivolumab with cisplatin and gemcitabine in muscle-invasive bladder cancer patients undergoing radical cystectomy. (2018) (4)
Difference in MRI-guided biopsy cancer detection rates between individual clinicians. (2019) (4)
BLUE LIGHT FLEXIBLE CYSTOSCOPY (BLFC) WITH HEXAMINOLEVULINATE (HAL) AND WHITE LIGHT FLEXIBLE CYSTOSCOPY: A PROSPECTIVE, COMPARATIVE, WITHIN‐PATIENT CONTROLLED MULTI‐CENTER PHASE 3 STUDY IN THE DETECTION OF BLADDER CANCER DURING SURVEILLANCE: PPTLBA‐02 (2017) (4)
Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology. (2019) (4)
ROLE OF LONG NON‐CODING RNA PVT1 IN REGULATING MYC IN HUMAN CANCER: MP99‐18 (2017) (4)
A phase IIa randomized placebo-controlled trial of pomegranate fruit extract/POMx in subjects with clinically localized prostate cancer undergoing active surveillance. (2020) (4)
RESULTS FROM THE SAN FRANCISCO FIREFIGHTERS BLADDER CANCER SCREENING STUDY (2008) (4)
Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy: Rosser CJ, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ, Division of Urology, University of Florida, Jacksonville, FL (2007) (4)
MP61-06 INCREASED PVT1 EXPRESSION CORRELATES WITH ADVANCED STAGE AND HORMONE RESISTANCE OF PROSTATE CANCER (2015) (4)
Health Disparities of Sexual Minority Patients Following Prostate Cancer Treatment: Results From the Restore-2 Study (2022) (4)
Alvimopan as part of the Enhanced Recovery After Surgery protocol following radical cystectomy is associated with decreased hospital stay (2021) (4)
232: Inpatient Costs for Bladder, Kidney, and Prostate Cancers in the Year 2002. A Study using the NIS Sample (2006) (3)
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons (2021) (3)
Identifying and treating ROBO1-ve /DOCK1+ve prostate cancer: An aggressive cancer subtype prevalent in African American patients. (2020) (3)
Is the complication rate of radical cystectomy predictive of the complication rate of other urological procedures? (2009) (3)
Is a nerve (graft) still a nerve by any other name? (2004) (3)
A cost containment strategy for radical retropubic prostatectomy: Results from implementation of a clinical pathway program. (1996) (3)
Patterns of primary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE (2006) (3)
Web-Accessible Interactive Software of 3D Anatomy Representing Pathophysiological Conditions to Enhance the Patient-Consent Process for Procedures (2011) (3)
855 ADVERSE EVENTS ASSOCIATED WITH THE DAVINCI SURGICAL SYSTEM AS REPORTED IN THE FDA MAUDE DATABASE (2013) (3)
24: Race and Outcome Following Radical Cystectomy: The Effect of Hospital Volume (2006) (3)
Trends in PET Scan Usage for Imaging of Patients Diagnosed With Nonmetastatic Urologic Cancer. (2016) (3)
Correction: BMI1, Stem Cell Factor Acting as Novel Serum-biomarker for Caucasian and African-American Prostate Cancer (2013) (3)
Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. (2021) (3)
Racial/Ethnic Differences in Health-Related Quality of Life Among Gay and Bisexual Prostate Cancer Survivors (2022) (3)
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial (2021) (3)
Hepatocellular carcinoma metastatic to the bladder after liver transplantation. (1999) (3)
Impact of Preoperative Immunonutrition on Perioperative Outcomes following Cystectomy (2021) (3)
A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT. (2020) (3)
155: Analysis of Long-Term Outcomes from Intervention for Bladder Cancer: Interim Results from the Iowa Bladder Cancer Outcomes Study (BCOS) (2004) (3)
Sickness and survival in bladder cancer: is comorbidity the crystal ball? (2008) (3)
Studying the impact of comorbidity on post radical cystectomy survival: have we come a full circle? (2019) (3)
1475 QUALITY OF CARE FOR PATIENTS WITH HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER (2010) (3)
Prostate-specific antigen screening in elderly men (2011) (2)
A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer (2019) (2)
Evidence-based medicine in urology (2011) (2)
Abstract 1586: Developing novel inhibitors of S100A4 for neuroendocrine (NE) and metastatic prostate cancer: systematic testing using relevant models and drug development techniques (2017) (2)
Tolterodine for overactive bladder. (1998) (2)
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. (2022) (2)
The Role of Extensive Lymphadenectomy in Upper Tract Malignant Disease (2014) (2)
UTILIZATION OF THE BLADDER CANCER SPECIFIC NUCLEAR MATRIX PROTEIN: BLCA-4, FOR THE DETECTION OF BLADDER CANCER (1999) (2)
Panning for prostate gold: urine based markers for prostate cancer. (2009) (2)
Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis (2016) (2)
TREXIT Is Now: Should We Abandon the Transrectal Route for Biopsy? A Three-continent Debate—No (2021) (2)
OLDER AGE AND TIME TO LAST BIOPSY ARE ASSOCIATED WITH RISE IN GLEASON SCORE FOR MEN ON ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER (2008) (2)
The monetary costs of pediatric upper urinary tract stone disease: Analysis in a contemporary United States cohort. (2022) (2)
Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context. (2020) (2)
THE ROLE OF URETHRAL FROZEN SECTION AT CYSTECTOMY IN THE MANAGEMENT OF BLADDER CANCER (2008) (2)
Prostate‐specific antigen testing in the elderly: a hard habit to kick? (2006) (2)
Characterization of Novel Murine and Human PDAC Cell Models: Identifying the Role of Intestine Specific Homeobox Gene ISX in Hypoxia and Disease Progression1 (2019) (2)
Of Albert Schweitzer and global urology. (2013) (2)
MP71-08 FINASTERIDE DOES NOT PREVENT BLADDER CANCER: A SECONDARY ANALYSIS OF THE MEDICAL THERAPY FOR PROSTATIC SYMPTOMS STUDY (2018) (2)
Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor (2020) (2)
Potential patient harms from misinterpretation of publically reported surgical outcomes (2019) (2)
The Challenge of Coming Out to Providers by Gay and Bisexual Men With Prostate Cancer: Qualitative Results from the Restore Study (2021) (2)
Diagnosis and Evaluation of Upper Tract Urothelial Carcinoma (UTUC) (2015) (2)
11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer (2007) (2)
Long-term treatment of metastatic renal-cell carcinoma with fluorouracil. (2004) (2)
Renal Pelvis and Ureter (2017) (2)
33: Complications Following Radical Cystectomy: Population Based Data (2006) (2)
Abstract LB-017: Minnelide reduces castration-resistant and enzalutamide-resistant prostate cancer via downregulation of androgen receptor-mediated signaling (2015) (2)
Lymphadenectomy for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. (2018) (2)
Bladder cancer prevention--could a carrot be the stick? (2006) (2)
Recruiting an underserved, difficult to reach population into a cancer trial: Strategies from the Restore-2 Rehabilitation Trial for gay and bisexual prostate cancer patients (2022) (2)
Management of Bladder Cancer (2015) (2)
The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer. (2017) (2)
174: Where are Patients with Major Urologic Cancers Undergoing Surgery? Changing Trends in Delivery of Surgical and non-surgical care (2005) (2)
Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology. (2021) (2)
Patient selection criteria for orthotopic bladder replacement (2004) (2)
Prostate cancer disclosure and sexual orientation: Understanding outness to healthcare providers as a situational or consistent phenomenon. (2021) (1)
GEMCITABINE AND MITOMYCIN INTRAVESICAL THERAPY IN PATIENTS WITH RECURRENT BLADDER CANCER REFRACTORY TO BCG (2008) (1)
Patterns of primary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE. (2007) (1)
Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease? (2018) (1)
The Need for Interim Assessment of Neoadjuvant Chemotherapy Response for Muscle Invasive Bladder Cancer: Can We Help Prevent Definitive Treatment Delay in Non-responders? (2020) (1)
Clinical Utility of Rigid Blue Light Cystoscopy: Results from a Post Procedure User Survey in a Prospective Multicenter Registry (2021) (1)
Anatomy, variants and anastomoses of prostatic arteries (2014) (1)
LOWER URINARY TRACT AND BOWEL SYMPTOMS PREDICT QUALITY OF LIFE IN GAY AND BISEXUAL PROSTATE CANCER SURVIVORS (2019) (1)
612: Pathologic Outcomes for Men on Active Surveillance who Undergo Radical Prostatectomy do not Differ from Men Undergoing Immediate Treatment (2007) (1)
6017 Detection and grading of prostate cancer using model-based spectral fitting (2013) (1)
PD39-12 IMPACT OF DELAY TO CYSTECTOMY IN NON RESPONDERS TO NEOADJUVANT CHEMOTHERAPY (NACT) PRIOR TO RADICAL CYSTECTOMY (RC) IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. (2016) (1)
571: Association between Post-Cystectomy Outcomes and Complications Following other Common Urologic Procedures (2007) (1)
Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system (2006) (1)
Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes (2016) (1)
UroVysionTM Testing Can Lead to Early Identification of Intravesical Therapy Failure in Patients with High Risk Non-Muscle Invasive Bladder Cancer (2009) (1)
GEOGRAPHIC VARIATION OF INFECTIOUS COMPLICATIONS FOLLOWING PROSTATE BIOPSY IN THE UNITED STATES: RESULTS FROM A POPULATION-BASED COHORT OF PRIVATELY INSURED PATIENTS. (2022) (1)
MP06-18 PREVALENCE OF CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS AFTER RADICAL CYSTECTOMY AND NEOADJUVANT CHEMOTHERAPY (2016) (1)
Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review (2021) (1)
META-ANALYSIS: DOES LIDOCAINE GEL PRIOR TO FLEXIBLE CYSTOSCOPY PROVIDE PAIN RELIEF? (2008) (1)
Outcomes and quality of care in urology. (2009) (1)
Alvimopan as an essential component of ERAS protocol to decrease length of hospital stay. (2020) (1)
Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (2017) (1)
Sipuleucel-T immunotherapy in clinical practice: Patient characteristics, tolerability, and survival. (2012) (1)
Prostate specific antigen screening and active surveillance in the elderly. (2009) (1)
Physicians, Internet and the vox populi. (2013) (1)
American Urological Association ( AUA ) Guideline EARLY DETECTION OF PROSTATE CANCER : AUA GUIDELINE (2018) (1)
The optimal management of clinically localized prostate cancer: the debate continues (2007) (1)
DECREASING TIME TO DETECTION: USE OF FLUORESCENCE IN SITU HYBRIDIZATION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER TUMORS UNDERGOING INTRAVESICAL THERAPY (2008) (1)
Critical evaluation and risk: Elderly patient undergoing (2007) (1)
MP23-20 BLUE LIGHT CYSTOSCOPY FOR DIAGNOSIS OF UROTHELIAL BLADDER CANCER: RESULTS FROM A PROSPECTIVE MULTICENTER REGISTRY (2016) (1)
MP78-12 UNDERUTILIZATION OF RADICAL PROSTATECTOMY IN LOCALIZED, HIGH-RISK PROSTRATE CANCER: OUTCOMES FROM A POPULATION COHORT (2014) (1)
Differences in quantitative urine composition in stone-forming versus unaffected mate kidneys (2009) (1)
Drain fluid creatinine-to-serum creatinine ratio as an initial test to detect urine leakage following cystectomy: A retrospective study (2021) (1)
1755 QUALITY OF CARE IN PATIENTS WITH BLADDER CANCER: THE NEED TO IMPROVE CARE BEYOND A CASE REPORT (2011) (1)
Contemporary Assessment of the Economic Burden of Upper Urinary Tract Stone Disease in the United States: Analysis of 1-year Healthcare Costs, 2011-2018. (2021) (1)
Complications rates of non-oncologic urologic procedures in population-based data: a comparison to published series. (2010) (1)
243: Ethnic Group-Related Differences in CPG Hypermethylation of the GSTP1 Gene Promoter among African American, Caucasian and Asian Patients with Prostate Cancer (2006) (1)
886: Bladder Cancer Incidence and Risk Factors Among Men with Prostate Cancer: Results from Capsuretm (2006) (1)
Management of stage T1b (A2) and stage T1c adenocarcinoma of the prostate. (1996) (1)
Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. (2021) (1)
Contemporary lymphadenectomy templates: kidney, prostate and bladder cancer (2014) (1)
606: Wnt Inhibitory Factor-1 Plays an Important Role in Pathogenesis of Bladder Cancer Through the Epigenetic Inactivation (2006) (1)
A Qualitative Study of Motivations for Minority Recruitment in Cancer Clinical Trials Across Five NCI-Designated Cancer Centers (2017) (1)
In-office urinary markers for bladder Ca: What's new (2004) (1)
Botryoid rhabdomyosarcoma of the bladder. (1997) (1)
MP24-06 GENDER BASED VARIATIONS IN THE DETECTION OF BLADDER CANCER WITH BLUE LIGHT CYSTOSCOPY: INSIGHTS FROM A MULTICENTER REGISTRY (2020) (1)
PD41-10 ROBOTIC RADICAL CYSTECTOMY IS ASSOCIATED WITH SHORTER LENGTH OF STAY AND LESS BLOOD LOSS THAN OPEN RADICAL CYSTECTOMY: RESULTS FROM A LARGE MULTICENTER RETROSPECTIVE COHORT (2018) (1)
MP24-06 A MULTI-INSTITUTIONAL STUDY FINDS THAT COMBINING THE 4KSCORE AND MPMRI REDUCES PROSTATE BIOPSY MORE THAN EITHER TEST ALONE (2019) (1)
Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study (2019) (1)
Cystic teratoma of the ovary mimicking a bladder stone. (1996) (1)
611: Baseline Characteristics and Predictors of Progression in an Active Surveillance Cohort: The UCSF Experience (2007) (1)
7 HIGH RISK PROSTATE CANCER FEATURES ON DIAGNOSIS IN AFRICAN AMERICAN MALES: ANALYSIS OF THE MODERN SEER DATABASE (2010) (1)
VITAMIN D INDUCED APOPTOSIS OF BLADDER TUMOR CELLS IN VITRO (1999) (1)
BLUE LIGHT CYSTOSCOPY FOR DIAGNOSIS OF UROTHELIAL BLADDER CANCER: RESULTS FROM A PROSPECTIVE MULTICENTER REGISTRY: MP15‐02 (2017) (1)
PD40-03 RACIAL DISPARITIES IN MAGNETIC RESONANCE IMAGING-GUIDED BIOPSY FOR THE DIAGNOSIS OF PROSTATE CANCER IN THE UNITED STATES (2020) (0)
Discrimination of Sexual and Gender Minority Patients in Prostate Cancer Treatment: Results from the Restore-1 Study. (2022) (0)
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. (2023) (0)
Supravesical urinary diversion (2012) (0)
2202 TRENDS IN PET SCAN UTILIZATION FOR IMAGING OF UROLOGIC CANCERS (2013) (0)
1486: Prevalence of Prostate Specific Antigen Screening in Men > 75 Years at an Academic Medical Center (2005) (0)
378: Bladder Cancer Treatment and the Volume-Outcome Relationship: Lessons from Radical Cystectomy (2004) (0)
THE IMPACT OF STATE LAWS LIMITING MALPRACTICE AWARDS ON DIFFUSION OF SURGICAL INNOVATION: THE CASE OF MINIMALLY INVASIVE RADICAL PROSTATECTOMY: MP69‐20 (2017) (0)
HAVE PATHOLOGIC AND FUNCTIONAL OUTCOMES AFTER RADICAL PROSTATECTOMY IMPROVED OVER TIME? ANALYSIS OF A NATIONAL DISEASE REGISTRY (2008) (0)
PD52-11 HEALTH RELATED QUALITY OF LIFE OUTCOMES BY URINARY DIVERSION: AN ANALYSIS FROM THE RANDOMIZED ROBOTIC VERSUS OPEN RADICAL CYSTECTOMY (RAZOR) TRIAL (2019) (0)
PD16-08 COST-EFFECTIVENESS OF SYSTEMIC TREATMENT INTENSIFICATION IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (2023) (0)
A Motion Tracking and Sensor Fusion Module for Medical Simulation (2016) (0)
Interview with Dr Badrinath Konety (2008) (0)
MP49-19 COMPARATIVE EVALUATION OF HEALTH RELATED QUALITY OF LIFE (HRQOL) INSTRUMENTS FOR BLADDER CANCER. (2016) (0)
Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy. (2023) (0)
MP51-12 NATIONAL CANCER SCREENING DISPARITIES AND TRENDS OF AFRICAN AMERICANS COMPARED TO CAUCASIAN AMERICANS FROM 2000-2015 (2018) (0)
Adjuvant chemo for bladder cancer: Are we closer to the truth? (2008) (0)
MP04-14 PHASE IIA, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SINGLE HIGH DOSE CHOLECALCIFEROL (VITAMIN D3) AND DAILY GENISTEIN (G-2535) VERSUS PLACEBO IN MEN WITH EARLY STAGE PROSTATE CANCER UNDERGOING PROSTATECTOMY (2016) (0)
Questions and Concerns of Robotic Approaches to Bladder Cancer Surgery (2014) (0)
MP32-10 COMPARATIVE EFFECTIVENESS OF ROBOTIC ASSISTED AND OPEN RADICAL CYSTECTOMY IN CONTEMPORARY COHORTS OF BLADDER CANCER PATIENTS: AN INTERNATIONAL MULTICENTER COLLABORATION (2019) (0)
536: Multi-Gene Methylation Analysis For Detection and Staging of Prostate Cancer (2006) (0)
Prevalence and Risk Factors for Sexually Transmitted Infections in Gay and Bisexual Prostate Cancer Survivors: Results From the Restore-2 Study (2022) (0)
Salvage Therapies for Non-Muscle Invasive Bladder Cancer (2020) (0)
738 THE EFFECT OF AGE OF ONSET AND CANCER SITE ON THE CAUSES OF LONG TERM MORTALITY IN PATIENTS DIAGNOSED WITH GERM CELL TUMORS (2012) (0)
MP73-07 INTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER CANCER: A COST ANALYSIS (2020) (0)
MP13-12 PROLONGED OPERATIVE TIME COULD BE A USEFUL METRIC TO PREDICT POSTOPERATIVE COMPLICATION AND READMISSION RATES (2021) (0)
7567 Pixel-Wise Multi-Parametric Assessment of Prostate Cancer from Co-registered regions of Pathologically defined Disease (2013) (0)
MP41-19 THE EFFECT OF SMOKING ON RADICAL CYSTECTOMY SURGICAL OUTCOMES: A PROPENSITY-MATCHED ANALYSIS (2018) (0)
78 INTENSITY-MODULATED RADIOTHERAPY REPLACES 3-DIMENSIONAL EXTERNAL BEAM AS THE PREFERRED RADIOTHERAPY MODALITY IN PROSTATE CANCER (2011) (0)
Faculty Opinions recommendation of Radical prostatectomy versus observation for localized prostate cancer. (2016) (0)
MP05-18 DISPARITIES IN BLADDER CANCER TREATMENT AND SURVIVAL AMONGST ELDERLY PATIENTS WITH A PRE-EXISTING MENTAL ILLNESS (2019) (0)
THE ASSOCIATION BETWEEN INSURANCE STATUS AND PROSTATE CANCER RISK CATEGORY AT PRESENTATION (2008) (0)
EDITORIAL COMMENT. (2020) (0)
Blue light cystoscopy for diagnosis of urothelial bladder cancer: Results from a multicenter registry (2018) (0)
MP41-18 THE IMPACT OF SARCOPENIA AND OBESITY ON THE TOLERABILITY OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER (2021) (0)
MP17-11 ACTIVE SURVEILLANCE FOLLOW-UP STRATEGIES: A COST-EFFECTIVENESS ANALYSIS (2018) (0)
MP73-11 ROLE OF BLUE LIGHT CYSTOSCOPY IN DETECTING INVASIVE BLADDER TUMOR: DATA FROM MULTI-INSTITUTIONAL REGISTRY (2020) (0)
A novel highly specific and sensitive urine-based assay for the detection of bladder cancer (2002) (0)
In reply [5] (2007) (0)
MP2-01 TREATMENT PATTERNS IN PATIENTS WITH RECURRENT HIGH-RISK BLADDER CANCER (2014) (0)
Detection of Prostate cancer: Quantitative Multiparametric MR Imaging Models Developed Using Registered Correlative Histopathology 1 (2016) (0)
A Shared Decision-Making Approach to Assessing Prostate Cancer Risk: A Gay Diary Case Study (2018) (0)
Long-term oncologic outcomes of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer. (2014) (0)
Does periprostatic nerve block with local anesthetic reduce pain during prostate biopsy? (2007) (0)
MP64-14 OUTPATIENT CHEMOPROPHYLAXIS AND RATE OF DEEP VENOUS THROMBOSIS FOLLOWING RADICAL CYSTECTOMY (2015) (0)
Seminar section introduction Outcomes and quality of care in urology (2009) (0)
Abstract 1821: Identifying a novel mechanism underlying the enzalutamide and bicalutamide resistance in African-American prostate cancer patients (2016) (0)
Re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660-4. (2017) (0)
180: Outcome from Radical Cystectomy in “Specialized” Urology Hospitals: are they any Better? (2005) (0)
Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis (2018) (0)
575: Patierns of Care in Bladder and Upper Tract Urothelial Cancer: Data from the UDA Project (2007) (0)
1016: Does the Time Interval Between Prostate Biopsy and Radical Prostatectomy Affect Immediate Postoperative Outcomes? (2005) (0)
344 IMPACT OF OCCURRENCE OF AHRQ PATIENT SAFETY INDICATOR (PSI) EVENTS IN UROLOGIC CANCER PATIENTS ON COST AND LENGTH OF STAY (LOS) (2010) (0)
Abstract 4678: A novel nuclear transporter for androgen receptor and AR-variant-7 in castration resistant prostate cancer: Ideal therapeutic target (2015) (0)
Erratum to: A Qualitative Study of Motivations for Minority Recruitment in Cancer Clinical Trials Across Five NCI-Designated Cancer Centers (2017) (0)
Faculty of 1000 evaluation for Emerging therapies to prevent skeletal morbidity in men with prostate cancer. (2016) (0)
Variant Histology: Management Pearls (2021) (0)
MP63-05 OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A (2023) (0)
PD60-07 ACUTE KIDNEY INJURY WITH ENHANCED RECOVERY AFTER SURGERY PROTOCOL IN RADICAL CYSTECTOMY SURGERY (2020) (0)
Title Active surveillance for the management of prostate cancer in a contemporary cohort Permalink (2008) (0)
1767 RECURRENCE AND TREATMENT PATTERNS IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (2012) (0)
Abstract 5851: Identifying novel genetic mechanism underlying ADT resistance in African American patients (2018) (0)
VARIATIONS IN ACCRUAL AND RACE/ETHNICITY REPORTING IN UROLOGY AND NON‐UROLOGY RELATED CANCER TRIALS.: MP32‐06 (2017) (0)
MP21-19 PREVALENCE OF MRI USE IN PATIENTS RECEIVING TREATMENT FOR PROSTATE CANCER (2016) (0)
1645 PREDICTING THE EXTENT OF LYMPHADENECTOMY DURING RADICAL CYSTECTOMY FOR BLADDER CANCER (2010) (0)
Abstract A008: Neoadjuvant nivolumab, gemcitabine and cisplatin in muscle-invasive bladder cancer: Study update (2019) (0)
Prostate Cancer in Older Adults (2014) (0)
Factors affecting the risk of erroneous interpretation of online surgeon rating websites among the general population. (2017) (0)
126 Prognostic model for predicting survival in patients with disease recurrence following radical cystectomy (2014) (0)
Predictors of clinically significant disease on systematic cores only in magnetic resonance imaging-guided prostate biopsy (2020) (0)
Effect of retinoic acid on in vitro and in vivo growth of netasta - tic prostate cancer cells (1992) (0)
PD14-06 IS A RESTAGING TURBT NECESSARY IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER IF THE INITIAL TURBT WAS PERFORMED USING BLUE LIGHT? (2022) (0)
MP06-17 COMPARISON OF OUTCOMES IN PATIENTS UNDERGOING CYSTECTOMY RECEIVING L-ARGININE IMMUNONUTRITION (2018) (0)
Urologic complications of hysterectomy in California (2009) (0)
Faculty Opinions recommendation of Contemporary trends in low risk prostate cancer: risk assessment and treatment. (2016) (0)
Commentary on the etiologic relationship between prostate radiation and bladder cancer: the scourge for one is poison for the other. (2008) (0)
PD41-12 THE BURDEN OF POST-OPERATIVE CLOSTRIDIUM DIFFICILE INFECTION IN RADICAL CYSTECTOMY CASES: A NATIONAL INPATIENT SAMPLE ANALYSIS (2018) (0)
Unrecognized sexual dysfunction in gay and bisexual men after prostate cancer treatment: the antecedents and impact of anodyspareunia. (2023) (0)
18of Care Indicators for Radical Cystectomy (2010) (0)
Strategic Planning and Essential Steps for Establishing a Uterine Transplant and Rehabilitation Program (2021) (0)
Reply to Diana A. Castillo-Jimenez and Herney A. García-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-ri (2019) (0)
Novel endoscopic techniques for the detection of bladder cancer (2015) (0)
Basic and Translational ScienceReply (2010) (0)
1327: Current Status of Clinical Trials in Urothelial Cancers: A Summary from the ACOSOG Gu Working Group (2005) (0)
Centralization of Health Care to Facilitate Greater Use of Nephron-Sparing Surgery for Localized Renal Tumors: Identifying Appropriate Health Care Delivery (2020) (0)
Editorial comment. (2011) (0)
Faculty Opinions recommendation of Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. (2007) (0)
Predictors of negative targeted prostate biopsy despite PIRADS 4-5 lesions on multiparametric magnetic resonance imaging (2020) (0)
Optimum threshold of the 4Kscore for biopsy in men with negative or indeterminate multiparametric magnetic resonance imaging (2023) (0)
Reply by Authors. (2020) (0)
MP32-20 PREDICTORS OF POSTOPERATIVE HEALTH-RELATED QUALITY OF LIFE (HRQOL): AN ANALYSIS FROM THE RAZOR TRIAL (2019) (0)
Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications (2018) (0)
Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification (2022) (0)
Focal Therapy for Prostate Cancer: A Molecular Biology Approach with TRAIL (2017) (0)
Multi-institutional review of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle-invasive bladder cancer. (2012) (0)
1598 FEASIBILITY STUDY: A NOVEL ULTRA-SMALL FIDUCIARY MARKER DESIGN AND DELIVERY PROTOCOL TO IMPROVE CONFORMAL RADIATION THERAPY FOR BLADDER CANCER (2011) (0)
Urinary and Bowel Symptoms Among Gay and Bisexual Prostate Cancer Survivors and Their Associations with Quality of Life (2023) (0)
950 IMPACT OF PRIOR LOCAL THERAPY ON SURVIVAL IN MEN RECEIVING CHEMOTHERAPY FOR METASTATIC PROSTATE CANCER (2012) (0)
Chapter 126 – Staging and Management of Prostate Cancer (2004) (0)
Review of Prostate Artery Embolization for Benign Prostatic Hypertrophy (2016) (0)
Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Twenty-First Century Edition. (2020) (0)
Value of Reflex ImmunoCyt Testing for the Diagnosis of Bladder Cancer (2012) (0)
Training Needs of Clinical and Research Professionals to Optimize Minority Recruitment and Retention in Cancer Clinical Trials (2017) (0)
Re: results from three municipal hospitals regarding radical cystectomy on elderly patients. (2008) (0)
Genomic characterization of variant histology muscle invasive bladder cancer (MIBC) to predict response to therapy. (2018) (0)
PHASE I TRIAL OF Ad5-TRAIL-MEDIATED GENE TRANSFER IN MEN WITH LOCALLY-CONFINED PROSTATE CANCER PRIOR TO PLANNED RADICAL PROSTATECTOMY (2008) (0)
28: Current Trends in the Preoperative Evaluation of Bladder Cancer Patients in the United States (2006) (0)
MP43-11 GEOGRAPHIC VARIATION OF INFECTIOUS COMPLICATIONS FOLLOWING PROSTATE BIOPSY IN THE UNITED STATES: RESULTS FROM A PRIVATELY INSURED COHORT (2021) (0)
My take: Test may help risk stratification (2010) (0)
Treatment patterns in patients with recurrent high-risk bladder cancer. (2014) (0)
Contents, Vol. 56, 1996 (1996) (0)
52 PROPOSAL FOR MONITORING UROLOGIC COMPLICATIONS OF HYSTERECTOMY IN CALIFORNIA USING PUBLICLY AVAILABLE DATA (2010) (0)
Preface to “Current and Future Topics on Prostate Cancer” (2021) (0)
1848 TRENDS IN THE RATE AND EXTENT OF PELVIC LYMPHADENECTOMY DURING RADICAL PROSTATECTOMY AND RADICAL CYSTECTOMY (2011) (0)
MP08-17 BLUE LIGHT CYSTOSCOPY IMPROVES DETECTION RATES FOR UROTHELIAL BLADDER CANCER COMPARED TO WHITE LIGHT CYSTOSCOPY: UPDATED RESULTS FROM A PROSPECTIVE MULTICENTER REGISTRY (2018) (0)
Urologic cancers: Where are we now and where is the field going? (2012) (0)
Faculty Opinions recommendation of Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. (2016) (0)
Complication rates of common urologic procedures in population-based data: A comparison with published series (2009) (0)
Identifying immune-related biomarkers to predict clinical outcomes of neoadjuvant immuno-chemotherapy (nivolumab, gemcitabine and cisplatin) in muscle-invasive bladder cancer (NCT03294304) (2020) (0)
Diagnosing Prostate Cancer: The Role of Intravesical Prostatic Gland Protrusion on Accuracy of Prostate Biopsies (2022) (0)
Managing Advanced Renal Cell Carcinoma T A B l E O f C O N T E N T S T A B l E O f C O N T E N T S (2009) (0)
MP01-19 UTILIZATION PATTERNS OF INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR PATIENTS WITH HIGH-GRADE, NON-MUSCLE INVASIVE BLADDER CANCER (2016) (0)
PD25-06 PRE-OPERATIVE INCIDENCE OF DEEP VENOUS THROMBOSIS IN BLADDER CANCER PATIENTS PRIOR TO UNDERGOING RADICAL CYSTECTOMY (2015) (0)
MP38-20 HEALTH CARE COSTS AND HOSPITAL READMISSIONS FOR RADICAL CYSTECTOMY FOR BLADDER CANCER BY SURGICAL APPROACH AND DIVERSION (2021) (0)
My take: Consider detection rate differences (2010) (0)
Sex steroid hormone effects of organochlorines, possible role in carcinogenicity (2005) (0)
LONG TERM OUTCOME OF RADICAL CYSTECTOMY AND ORTHOTOPIC NEOBLADDER DIVERSION IN WOMEN: THE UCSF EXPERIENCE (2008) (0)
Faculty Opinions recommendation of Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. (2016) (0)
MP55-13 TRIPTOLIDE INHIBIT CASTRATE RESISTANT AND ENZALUTAMIDE RESISTANT PROSTATE CANCER GROWTH BY DECREASING ANDROGEN RECEPTOR FULL LENGTH AND SPLICE VARIANTS EXPRESSION (2015) (0)
Misinterpretation of online surgical outcomes: The British Association of Urological Surgeons Surgical Outcomes Audit (2018) (0)
PHYSIOLOGICAL EVIDENCE OF DNA DAMAGE BY CARCINOGENS KNOWN TO BE PRESENT IN CHARRED AND PROCESSED MEATS (PHIP DNA ADDUCTS), IN A SMALL COHORT OF PROSTATE CANCER PATIENTS.: MP28‐02 (2017) (0)
Biodegradable nerve grafts--physiologically and environmentally friendly? (2005) (0)
MP44-17 A NATIONAL SURVEY OF RADIATION ONCOLOGISTS AND UROLOGISTS ON PREDICTION TOOLS AND NOMOGRAMS FOR LOCALIZED PROSTATE CANCER (2019) (0)
Impact of Preoperative Immunonutrition on Perioperative Outcomes Following Cystectomy. Reply. (2021) (0)
PD50-08 MRI, BIOMARKER, OR BOTH? RESULTS FROM A LARGE MULTI-INSTITUTIONAL STUDY OF 1111 MEN WITH 4KSCORE, MULTIPARAMETRIC MRI AND PROSTATE BIOPSY (2021) (0)
480: Smoking Influences Aberrant CPG Hypermethylation of Multiple Genes in Human Prostate Cancer (2006) (0)
MP80-05 PSA LEVEL PREDICTS POSITIVITY OF 18F-FLUCICLOVINE PET/CT IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER (2019) (0)
Phase I/Ib study of enzalutamide and gemcitabine and cisplatin in bladder cancer. (2017) (0)
PD41-12 THE DIAGNOSTIC ACCURACY OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN STAGING MUSCLE-INVASIVE BLADDER CANCER PATIENTS (2015) (0)
Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light? (2022) (0)
114 AHRQ PATIENT SAFETY INDICATORS (PSIS) AND UROLOGIC CANCER HOSPITALIZATIONS (2010) (0)
The Effects of Prostate Cancer Treatment on Role-In-Sex in Gay and Bisexual Men: Mixed Methods Results from the Restore-1 and Restore-2 Studies. (2022) (0)
ESTIMATION OF MORTALITY AND MORBIDITY RISK IN PATIENTS UNDERGOING RADICAL CYSTECTOMY WITH CONTINENT DIVERSION USING THE POSSUM AND PORTSMOUTH POSSUM PREDICTOR EQUATIONS (2008) (0)
Editorial comment. (2010) (0)
MP5-04 RISK OF END STAGE KIDNEY DISEASE AFTER RADICAL CYSTECTOMY ACCORDING TO TYPE OF URINARY DIVERSION (2014) (0)
Use of Synthetic Nerve Grafts to Restore Cavernous Nerve Function Following Prostate Cancer Surgery: In Vitro and In Vivo Studies (2005) (0)
Therapeutic strategies in stage a prostate cancer (1993) (0)
Advances in nonmuscle invasive bladder cancer (2015) (0)
Finasteride-Nemesis of More Than 1 Urological Cancer? (2018) (0)
Transitional cell carcinoma of the renal pelvis and ureter: Evaluation and treatment (2005) (0)
Advances in Brief Detection of Bladder Cancer Using a Novel Nuclear Matrix Protein , BLCA-41 (2000) (0)
Bladder Cancer and Other Urothelial Sites (2018) (0)
Treatment of superficial bladder cancer (2010) (0)
PD08-08 RACIAL DISPARITIES IN THE FREQUENCY AND INTENSITY OF ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER (2016) (0)
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States: Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT, Department of Urology, University of Michigan, Ann Arbor, MI (2007) (0)
The Effects of Radiation Therapy for Prostate Cancer on Gay and Bisexual Men’s Experiences of Mental Health, Sexual Functioning and Behavior, Sexual Identity, and Relationships (2018) (0)
20: Profiling Post-Operative Risk in Elderly Patients Undergoing Urologic Cancer Surgery (2006) (0)
Reply by Authors. (2022) (0)
945 ZOLEDRONIC ACID USE IS ASSOCIATED DECREASED RISK OF BONE FRACTURES IN MEN WITH METASTATIC PROSTATE CANCER: A POPULATION-BASED STUDY (2012) (0)
Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. (2023) (0)
Identifying and treating ROBO1 − ve /DOCK1 +ve prostate cancer: An aggressive cancer sub-type prevalent in African-American patients (2020) (0)
272 BLADDER CANCER IN THE US – ARE COMMON RECOMMENDATIONS FOR INITIAL DIAGNOSIS FOLLOWED IN DAILY CLINICAL PRACTICE? (2010) (0)
MP66-14 IDENTIFYING NOVEL NUCLEAR TRANSPORTER OF AR AND AR(VARIANT) IN CRPC CELLS: POTENTIAL IMPLICATIONS IN THERAPY (2015) (0)
National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. (2021) (0)
ERRONEOUS INTERPRETATION OF ONLINE SURGICAL SCORECARD MAY HARM PATIENTS BY INCREASING WILLINGNESS TO PAY OUT‐OF‐POCKET EXPENSES FOR A VANISHINGLY LOW CHANCE OF LOWERING THE POSTOPERATIVE COMPLICATION RISK: MP32‐18 (2017) (0)
MP61-14 READMISSION RATES AND THEIR PREDICTORS AFTER ROBOTIC AND OPEN RADICAL CYSTECTOMY (2020) (0)
525 ADHERENCE TO GUIDELINE RECOMMENDATIONS ON INITIAL DIAGNOSIS OF BLADDER CANCER - IS THERE AN IMPACT ON PATIENTS OUTCOME? (2013) (0)
Bioprinting: 3D Printed Organ Models with Physical Properties of Tissue and Integrated Sensors (Adv. Mater. Technol. 3/2018) (2018) (0)
678: Recovery of Urinary Continence Following Radical Prostatectomy: The Impact of Prostate Volume (2006) (0)
Patterns of minimally invasive radical prostatectomy (MIRP) versus open radical retropubic prostatectomy (ORP) in patients older than 70 (2012) (0)
Association of Surgical Approach and Urinary Diversion in Radical Cystectomy for Bladder Cancer With Costs and Readmission: Results From a Large Private Health Insurance Cohort. (2022) (0)
Managing the primary in muscle-invasive bladder cancer (2021) (0)
Clinical applications of immunoscintigraphy for prostate cancer (2005) (0)
Reducing bladder cancer deaths (2009) (0)
MP71-09 FDG-POSITRON EMISSION TOMOGRAPHY FOR ASSESSING THE RESPONSE TO NEO-ADJUVANT CHEMOTHERAPY IN BLADDER CANCER PATIENTS (2018) (0)
Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed with Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care (2020) (0)
PD09-02 ANTI-ADENOVIRAL ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE IN BCG-UNRESPONSIVE NMIBC: RESULTS FROM A PHASE 3 TRIAL (2021) (0)
Multi-institutional review of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle-invasive bladder cancer. (2012) (0)
Faculty Opinions recommendation of Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. (2016) (0)
Active surveillance follow-up strategies: A cost-effectiveness analysis (2018) (0)
Subject Index Vol. 56, 1996 (1996) (0)
MP61-09 PREDICTORS OF POSTOPERATIVE COMPLICATIONS AFTER ROBOTIC AND OPEN RADICAL CYSTECTOMY (2020) (0)
The Reliability of Self-Reported Gleason Scores in Studies of Sexual Minority Prostate Cancer Survivors. (2020) (0)
Blue light cystoscopy for detection of invasive bladder tumor: Results from multi-institutional registry (2020) (0)
124: Access to and Survival from Radical Cystectomy for Bladder Cancer: The Impact of Caps on Non-Economic Damage Malpractice Awards (2004) (0)
MP78-14 DISPARITIES IN ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER BETWEEN AFRICAN AMERICAN AND CAUCASIAN MALES (2014) (0)
PD15-01 CHARACTERIZATION OF THE GENOMIC LANDSCAPE OF A PROSPECTIVE MUSCLE-INVASIVE BLADDER CANCER COHORT WITH A FOCUS ON SECONDARY VARIANT HISTOLOGY (2018) (0)
1765 ASSOCIATION OF COMORBIDITY, AGE AND AGGRESSIVE SURGICAL THERAPY FOR PROSTATE AND BLADDER CANCER (2013) (0)
The Sexual Functioning of Gay and Bisexual Men Following Prostate Cancer Treatment: Results from the Restore Study (2019) (0)
Outcomes after minimally invasive radical prostatectomy (MIRP) versus open radical prostatectomy (OPRP) in patients older than 70 (2012) (0)
Bladder cancer data must be taken in context (2009) (0)
MP62-02 RACIAL DISPARITIES IN MAGNETIC RESONANCE IMAGING-GUIDED BIOPSY FOR THE DIAGNOSIS OF PROSTATE CANCER IN THE UNITED STATES (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Badrinath R. Konety?

Badrinath R. Konety is affiliated with the following schools:

University of Minnesota
University of California, Los Angeles
Johns Hopkins University
University of Iowa
Rush University
University of California, San Francisco